中文名稱:ALK-IN-12 | 英文名稱:ALK-IN-12 |
CAS:1197958-53-4 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類別: 抑制劑 | |
貨號: T38584 |
名稱 | ALK-IN-12 |
描述 | ALK-IN-12 is a highly potent and orally active inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an exceptional IC50 value of 0.18 nM. Additionally, ALK-IN-12 displays inhibitory activity against insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. Notably, its antitumor effects have been observed, making it a promising compound for targeted cancer therapy. |
體外活性 | ALK-IN-12 (compound 11e) effectively inhibits viability of the Karpas-299 ALCL cell line with an IC 50 of 28.3 nM[1]. |
體內活性 | ALK-IN-12 (10-50 mg/kg; orally; once daily for 13 consecutive days) shows dose-dependent antitumor activity[1]. ALK-IN-12 (3 mg/kg; i.v.; 6-8 week old female CD rats ) treatment shows AUC 0-∞ , CL, t 1/2 and V ss are 3039 ng?h/mL, 0.91 h?kg, 6.6 hours and 6.12 L/kg, respectively[1]. ALK-IN-12 (10 mg/kg; p.o.; 6-8 week old female CD rats) treatment shows C max , AUC 0-∞ , t max , t 1/2 and F are 3254 ng/mL, 4056 ng?h/mL, 6.0 hours, 12.5 hours and 39%, respectively[1]. Animal Model: Eight- to 10-week old female SCID/beige mice (Karpas-299 xenograft mouse model expressing the NPM-ALK fusion)[1]Dosage: 10-50 mg/kg Administration: Orally; once daily for 13 consecutive days Result: Dose-dependent antitumor activity. Led to tumor stasis (50 mg/kg dose). |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關鍵字 | ALKIN12 | ALK IN 12 | ALK-IN-12 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 589.8595萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 中間體,天然產(chǎn)物,生物化工,化學試劑,生物技術服務 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-10-30 | |
詢價 |
VIP13年
|
上海厚博生物科技有限公司
|
2024-08-09 | |
¥1280 |
VIP1年
|
湖北艾普蒂生物工程有限公司
|
2024-10-30 |